Breast cancer+2
Not recruitingComparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation
Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation
- Disease:Breast cancerBreast cancer metastatic+1
- Substances:AlpelisibFulvestrant+3
Italy- Participants:18–64 years · 65+ years
- Substances:Alpelisib
- Sponsor:F. Hoffmann-La Roche AG














